华蟾素胶囊联合西妥昔单抗和FOLFOX4化疗在晚期结直肠癌患者中的应用效果

Application effects of Cinobufotalin combined with Cetuximab and FOLFOX4 chemotherapy in patients with advanced colorectal cancer

目的:观察华蟾素胶囊联合西妥昔单抗和FOLFOX4化疗在晚期结直肠癌患者中的应用效果。方法:选取2019年2月至2022年2月濮阳市人民医院收治的116例晚期结直肠癌患者进行前瞻性研究,按照随机数字表法分为观察组与对照组各58例。对照组采用西妥昔单抗联合FOLFOX4化疗,观察组在对照组基础上加用华蟾素胶囊治疗,比较两组近期疗效[客观缓解率(ORR)、疾病控制率(DCR)]、癌性疼痛缓解率和不良反应发生率。结果:观察组ORR为58.62%,高于对照组的39.66%,差异有统计学意义(P<0.05);两组DCR比较,差异无统计学意义(P>0.05)。观察组疼痛缓解率为87.93%,高于对照组的67.24%,差异有统计学意义(P<0.05)。治疗期间,观察组骨髓抑制发生率为39.66%,低于对照组的67.24%,差异有统计学意义(P<0.05)。结论:华蟾素胶囊联合西妥昔单抗和FOLFOX4化疗用于晚期结直肠癌患者可提高ORR、癌性疼痛缓解率,降低骨髓抑制发生率,效果优于单纯西妥昔单抗和FOLFOX4化疗。

Objective:To observe application effects of Cinobufotalin combined with Cetuximab and FOLFOX4 chemotherapy in patients with advanced colorectal cancer.Methods:A prospective study was conducted on 116 patients with advanced colorectal cancer admitted to the Puyang People’s Hospital from February 2019 to February 2022.They were divided into observation group and control group according to the random number table method,58 cases in each group.The control group was treated with Cetuximab combined with FOLFOX4 chemotherapy,while the observation group was treated with Cinobufotalin on the basis of that of the control group.The short-term efficacy[total effective rate(ORR),disease control rate(DCR)],the cancer pain relief rate,and the incidence of adverse reactions were compared between the two groups.Results:The ORR of the observation group was 58.62%,which was higher than 39.66% of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in DCR between the two groups(P>0.05).The pain relief rate of the observation group was 87.93%,which was higher than 67.24% of the control group,and the difference was statistically significant(P<0.05).Further,during the treatment,the incidence of myelosuppression in the observation group was 39.66%,which was lower than 67.24%in the control group,and the difference was statistically significant(P<0.05).Conclusions:Cinobufotalin combined with Cetuximab and FOLFOX4 chemotherapy for the patients with advanced colorectal cancer can improve the ORR and the cancer pain relief rate,and reduce the incidence of bone marrow suppression.Moreover,it is superior to single Cetuximab and FOLFOX4 chemotherapy.